Arcus Biosciences, Inc. announced a private placement of 15,238,096 common shares at a price of $21 per share for the gross proceeds of $320,000,016 on January 29, 2024. The transaction will include participation from returning investor Gilead Sciences, Inc. for 33% stake.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.71 USD | +3.47% | +6.43% | -12.51% |
05-08 | Transcript : Arcus Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (RCUS) ARCUS BIOSCIENCES Posts Q1 Revenue $145M | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
65.96 USD | +2.14% | +1.82% | 82.18B | ||
16.71 USD | +3.47% | +6.43% | 1.52B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.51% | 1.52B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $320.000016 million in funding from Gilead Sciences, Inc.